Crescendo Biologics

About:

Crescendo Biologics is engaged in the development of a proprietary drug portfolio based on their VH antibody fragment platform.

Website: http://www.crescendobiologics.com

Twitter/X: humabody

Top Investors: Andera Partners, Future Planet Capital, Takeda, Sofinnova Investments, IP Group

Description:

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Total Funding Amount:

$148M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2007-01-01

Contact Email:

info(AT)crescendobiologics.com

Founders:

Mike Romanos

Number of Employees:

51-100

Last Funding Date:

2023-07-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai